Figure 1A




Figure 1B




Figure 2



Insulin (mU/L)
150
100
50
0
-5
0
2
4
6
8
10
15
20
Time (min)
Bimagrumab
Placebo
Wk 1
Wk 10
AUC=−38% (90% CI −52.6, −19.0; p=0.008)
Cmax=−30.4% (90% CI −48.7, −5.6; p=0.056)

Figure 3



Fat Body Mass
regression: -4.375-0.063* x
p-value for slope: 0.041
% Change from Baseline
Insulin Sensitivity (MI) - Step I
% Change from Baseline
regression: -3.678-0.080* x
p-value for slope: 0.028
% Change from Baseline
Insulin Sensitivity (MI) - Step II
% Change from Baseline
Lean Body Mass
regression: 2.773+0.008* x
p-value for slope: 0.882
% Change from Baseline
Insulin Sensitivity (MI) - Step I
% Change from Baseline
regression: 2.393+0.017* x
p-value for slope: 0.411
% Change from Baseline
Insulin Sensitivity (MI) - Step II
% Change from Baseline
Bimagrumab
Placebo

Figure 4



HbA1c Absolute Change from Baseline (%)
0.2
0.1
0.0
-0.1
-0.2
***
*
Baseline
Wk 3 (D 22)
Wk 6 (D 43)
Wk 10 (D 71)
Wk 14 (D 99)
Wk 18 (D 127)
Wk 24 (D 169)
*p<0.05; ***p<0.0001
Bimagrumab
Placebo

Figure 5




Semilogarithmic view
1000
100
10
1
0.1
Concentration (µg/mL)
W1D1
W3D22
W6D43
W10D71
W14D99
W18D127
EOS
Time (days)
BYM338 30mg/kg

Figure 6


EOS
Screening baseline (3 weeks)
Treatment period (48 wks)
F-up 8 wks
Visit #
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Study day window
-21/-8 -7/-1 1 -2/+2 -2/+2 -2/+2 -2/+2 -2/+2 -2/+2 -5/+5 -5/+5 -5/+5 -5/+5 -5/+5 -5/+5 -5/+5 -5/+5
Wk - 3 Wk 0 Wk 4 Wk 8 Wk 12 Wk 16 Wk 20 Wk 24 Wk28 Wk32 Wk36 Wk40 Wk44 Wk48 Wk52 Wk56
Dosing time-points
IA 1: futility (50% pop)
IA 2: PoC (50% pop)
End of treatment period assessments